Article

Long-term safety of anecortave acetate studied in 24-month analysis

Alcon Laboratories Inc. reported 24-month data from its comparative study of anecortave acetate suspension (Retaane 15 mg) versus photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Ophthalmics/QLT Inc.) in the treatment of wet age-related macular degeneration (AMD).

The primary aim of the 24-month analysis was to confirm the long-term safety of anecortave acetate suspension, according to Alcon. Safety information from this study showed that no clinically relevant safety issues were observed due to the drug or the posterior juxtascleral depot procedure during the entire course of the study, the company said. Ocular and non-ocular adverse events were reported at similar rates in both arms of the study, reported the company.

In addition to the safety data, Alcon said 2-year data continued to show anecortave acetate suspension is clinically equivalent to PDT with verteporfin. Furthermore, the mean visual acuity for both treatment groups was clinically stable from month 12 to 24.

"We believe these data indicate that Retaane suspension has the potential to play a unique role in the chronic treatment of wet AMD," said Stella Robertson, PhD, Alcon's vice president, ophthalmic development, Fort Worth, TX. "We continue to have discussions with the FDA and other regulatory agencies around the world to gain approval of this drug."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.